top of page

The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

FoodBev Media Logo
Nov - Food Bev - Website Banner - TIJ vs TTO 300x250.gif
Access more as a FoodBev subscriber

Sign up to FoodBev and unlock more insights from the international food and beverage industry. Subscribers have access to webinars, newsletters, publications and more...

Siân Yates

Siân Yates

30 September 2025

Kemin enhances global enzyme production with CJ Youtell Biotech acquisition

Kemin enhances global enzyme production with CJ Youtell Biotech acquisition

Kemin Industries, a global ingredient manufacturer, has acquired CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio.


This acquisition enhances Kemin's enzyme production capabilities and solidifies its position as a frontrunner in enzyme innovation across multiple sectors, including animal feed, food processing, aquaculture, textiles and biofuels.


The acquisition grants Kemin full ownership of CJ Youtell's fermentation plants and its extensive enzyme product portfolio. Notably, CJ Youtell operates state-of-the-art fermentation facilities located in Shandong and Hunan, China, which will now be integrated into Kemin's existing operations.


This move is expected to streamline Kemin's supply chain and expand its market reach, enabling the company to deliver high-performance, sustainable enzyme technologies to a global customer base.


Chris Nelson, president and CEO of Kemin Industries, said: “We are pleased to welcome CJ Youtell into the Kemin family. This acquisition is a bold step forward in our ongoing strategy to provide cutting-edge fermentation solutions directly to our customers.”


Nelson also pointed out that the addition of CJ Youtell enhances Kemin’s ability to supply high-quality and innovative enzyme ingredients across various industries.


The acquisition is poised to bolster Kemin's research and development capabilities, with the newly acquired facilities supporting advanced laboratories and technical teams specialising in bioengineering and enzyme formulation.


This enhancement will enable Kemin to optimise production costs, reduce supply chain risks and offer competitively priced enzyme solutions tailored to the specific needs of its diverse clientele.


Michelle Lim, president of Kemin Enzymes, added: “For over 40 years, Kemin has been formulating and delivering enzyme solutions across multiple markets. With CJ Youtell's fermentation expertise now part of our portfolio, we offer customers a fully integrated solution – from proprietary strain development and manufacturing to final formulation and application support.”


By combining in-house fermentation with advanced formulation techniques and comprehensive technical support, Kemin is well-positioned to meet the evolving demands of its customers, ensuring they remain competitive in rapidly changing markets.


Kemin Industries, established in 1961, operates in over 90 countries and provides more than 500 specialty ingredients for human and animal health, nutrition and various industrial applications.

Related posts
Lallemand Bio-Ingredients acquires Solyve to enhance enzyme portfolio
Ingredients

Lallemand Bio-Ingredients acquires Solyve to enhance enzyme portfolio

Opinion: Three ways bioscience innovations are future-proofing the food and beverage industry
Exclusives

Opinion: Three ways bioscience innovations are future-proofing the food and beverage industry

DSM-Firmenich launches new coagulant enzyme to enhance cheese production
New products

DSM-Firmenich launches new coagulant enzyme to enhance cheese production

IFF launches Texstar enzyme solution to ‘transform’ fresh fermented food textures
Dairy

IFF launches Texstar enzyme solution to ‘transform’ fresh fermented food textures

IFF introduces Diazyme Nolo to enhance no- and low-alcohol beer production
Alcohol

IFF introduces Diazyme Nolo to enhance no- and low-alcohol beer production

Digestiva secures $18.4m in Series A funding to advance protein enzyme technology
Funding & Investments

Digestiva secures $18.4m in Series A funding to advance protein enzyme technology

DSM | Leader
bottom of page